Table 3 Multivariate analysis with survival of esophageal cancer post definitive chemotherapy.

From: A pilot study of tegafur-uracil maintenance on survival in patients with esophageal squamous cell carcinoma following definitive chemoradiotherapy

 

PFS

 

OS

 

Gender, Female vs. male

0.94 (0.46–1.94)

0.874

0.61 (0.25–1.51)

0.286

Age, ≤ 60 vs. > 60

0.84 (0.58–1.23)

0.371

0.83 (0.57–1.22)

0.940

BMI, > 23.5 vs. ≤ 23.5

0.79 (0.54–1.17)

0.243

0.75 (0.50–1.12)

0.157

T stage, T1-2 vs. T3-4

0.71 (0.48–1.05)

0.089

0.77 (0.52–1.13)

0.183

N stage, N0-1 vs. N2-3

0.64 (0.44–0.93)

0.020

0.70 (0.46–1.07)

0.102

Stage, I-II vs. III

0.62 (0.41–0.92)

0.022

0.65 (0.42–0.99)

0.046

CCRT response, CR + PR vs. SD

0.24 (0.15–0.40)

< 0.001

0.43 (0.26–0.73)

0.002

UFUR maintenance, yes vs. no

0.56 (0.37–0.86)

0.007

0.50 (0.32–0.78)

0.002

  1. PFS, progression-free survival; OS, overall survival; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; UFUR, tegafur/uracil.
Back to article page